帕博利珠单抗联合靶动脉灌注化疗治疗晚期NSCLC的效果及安全性分析  

Analysis on Effect and Safety of Pembrolizumab Combined with Target Artery Infusion Chemotherapy in the Treatment of Advanced NSCLC

作　　者：卢保华 张军伟 张俊杰 LU Baohua;ZHANG Junwei;ZHANG Junjie(1^(st) Department of Surgery,Zhoukou Hospital of Traditional Chinese Medicine,Zhoukou 466000,China;Department of Thoracic Surgery,Zhoukou Hospital of Traditional Chinese Medicine,Zhoukou 466000,China)

机构地区：[1]周口市中医院外一科,河南周口466000 [2]周口市中医院胸外科,河南周口466000

出　　处：《临床医学工程》2022年第7期961-962,共2页Clinical Medicine & Engineering

摘　　要：目的 探讨帕博利珠单抗联合靶动脉灌注化疗治疗晚期非小细胞肺癌(NSCLC)的效果及安全性。方法 将60例晚期NSCLC患者随机分为观察组(帕博利珠单抗联合靶动脉灌注化疗)与对照组(靶动脉灌注化疗)。比较两组的治疗效果及安全性。结果 观察组DCR、 ORR高于对照组,治疗后的CEA、 NSE水平低于对照组(P <0.05)。治疗后,两组的CD4^(+)、 CD8^(+)、CD4^(+)/CD8^(+)降低,且观察组的CD4^(+)、 CD8^(+)、 CD4^(+)/CD8^(+)低于对照组(P <0.05)。两组的毒副作用发生率比较无统计学差异(P>0.05)。结论 帕博利珠单抗联合靶动脉灌注化疗治疗晚期NSCLC的效果较好,可改善机体免疫状态,安全性较高。Objective To analyze the effect and safety of pembrolizumab combined with target artery infusion chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 60 patients with advanced NSCLC were randomly divided into observation group(pembrolizumab combined with target artery infusion chemotherapy) and control group(target artery infusion chemotherapy).The treatment effect and safety were compared between the two groups.Results The DCR and ORR of the observation group were higher than those of the control group,and the CEA and NSE levels after treatment were lower than those of the control group(P0.05).Conclusions Pembrolizumab combined with target artery infusion chemotherapy has better effect in the treatment of advanced NSCLC,which can improve the immune state with higher safety.

关 键 词：帕博利珠单抗 靶动脉灌注化疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]